Your browser doesn't support javascript.
loading
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022.
Plumb, Ian D; Mohr, Nicholas M; Hagen, Melissa; Wiegand, Ryan; Dumyati, Ghinwa; Harland, Karisa K; Krishnadasan, Anusha; Gist, Jade James; Abedi, Glen; Fleming-Dutra, Katherine E; Chea, Nora; Lee, Jane; Barter, Devra; Brackney, Monica; Fridkin, Scott K; Wilson, Lucy E; Lovett, Sara A; Ocampo, Valerie; Phipps, Erin C; Marcus, Tiffanie M; Smithline, Howard A; Hou, Peter C; Lee, Lilly C; Moran, Gregory J; Krebs, Elizabeth; Steele, Mark T; Lim, Stephen C; Schrading, Walter A; Chinnock, Brian; Beiser, David G; Faine, Brett; Haran, John P; Nandi, Utsav; Chipman, Anne K; LoVecchio, Frank; Talan, David A; Pilishvili, Tamara.
Affiliation
  • Plumb ID; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mohr NM; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Hagen M; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Wiegand R; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dumyati G; New York State Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, USA.
  • Harland KK; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Krishnadasan A; Department of Emergency Medicine, Olive View-UCLA Education and Research Institute, Los Angeles, California, USA.
  • Gist JJ; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Abedi G; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Fleming-Dutra KE; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chea N; National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lee J; Healthcare-Associated Infections, California Emerging Infections Program, Oakland, California, USA.
  • Barter D; Healthcare-associated Infections / Antimicrobial Resistance Program, Colorado Department of Public Health & Environment, Denver, Colorado, USA.
  • Brackney M; Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA.
  • Fridkin SK; Georgia Emerging Infections Program and Emory University School of Medicine, Atlanta, Georgia, USA.
  • Wilson LE; Maryland Emerging Infections Program, Maryland Department of Health, and University of Maryland, Baltimore County, Baltimore, Maryland, USA.
  • Lovett SA; Infectious Disease Epidemiology, Prevention and Control Divison, Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Ocampo V; Public Health Division, Oregon Health Authority, Portland, Oregon, USA.
  • Phipps EC; New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico, USA.
  • Marcus TM; Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Smithline HA; Department of Emergency Medicine, University of Massachusetts Chan Medical School - Baystate, Springfield, Massachusetts, USA.
  • Hou PC; Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Lee LC; Emergency Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
  • Moran GJ; David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
  • Krebs E; Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
  • Steele MT; Department of Emergency Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Lim SC; Section of Emergency Medicine, University Medical Center New Orleans, LSU Health Sciences Center, New Orleans, Louisiana, USA.
  • Schrading WA; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Chinnock B; Department of Emergency Medicine, University of California San Francisco, Fresno, California, USA.
  • Beiser DG; Section of Emergency Medicine, University of Chicago, Chicago, Illinois, USA.
  • Faine B; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Haran JP; Department of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Nandi U; Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Chipman AK; Emergency Department, University of Washington, Seattle, Washington, USA.
  • LoVecchio F; Emergency Medicine, Valleywise Health Medical Center, Phoenix, Arizona, USA.
  • Talan DA; David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
  • Pilishvili T; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Open Forum Infect Dis ; 10(10): ofad457, 2023 Oct.
Article in En | MEDLINE | ID: mdl-37799130
ABSTRACT

Background:

Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant.

Methods:

We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates.

Results:

Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants.

Conclusions:

A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Evaluation_studies Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Evaluation_studies Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article Affiliation country: United States